Table 3. Sensitivity analysis of multiple linear regression model with non-exclusive user of medicines.
2000 to 2015.
| Predictive variables | B | Standard Error | t value | p value |
|---|---|---|---|---|
| Intercept | 3,18E+29 | 2.048.707 | 33.158 | < 0.001 |
| South | 1,09 | 0.025158 | 3.255 | 0.001 |
| Northeast | 1,07 | 0.025732 | 2.463 | 0.014 |
| Southeast | 1,18 | 0.024516 | 6.611 | < 0.001 |
| Midwest | 1,19 | 0.026189 | 6.663 | < 0.001 |
| Intramscular interfeon beta 1a (Rebif™) | 1,17 | 0.008160 | 19.714 | < 0.001 |
| Subcuaneous interferona beta 1b (Betaferon™ or Extavia™) | 0,91 | 0.009006 | -10.076 | < 0.001 |
| Glatiramer (Copaxone™) | 0,88 | 0.009384 | -13.880 | < 0.001 |
| Natalizumab (Tysabri™) | 1,10 | 0.037908 | 2.418 | 0.016 |
| Azathioprine | 0,06 | 0.018689 | -150.254 | < 0.001 |
| Other DMT Combinations | 0,95 | 0.046405 | -1.109 | 0.268 |
| Year of treatment start | 0,97 | 0.001018 | -28.644 | < 0.001 |
| Treatment time | 1,02 | 0.001166 | 19.145 | < 0.001 |
| Registry of comorbidity | 0,89 | 0.007546 | -15.903 | < 0.001 |
| Treatment failure by relapse | 0,97 | 0.016993 | -1.836 | 0.066 |
| Treatment failure by switched medication | 0,93 | 0.006902 | -10.424 | < 0.001 |
| Treatment failure by death | 1,06 | 0.021090 | 2.749 | 0.006 |
| Treatment failure by relapse and switched medication | 0,91 | 0.014159 | -6.697 | < 0.001 |
| Treatment failure by relapse and death | 1,24 | 0.049005 | 4.420 | < 0.001 |
| Treatment failure by switched medication and death | 0,94 | 0.023526 | -2.499 | 0.012 |
| Treatment failure by relapse. switched medication and death | 1,00 | 0.039628 | -0.106 | 0.915 |